MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Third Quarter Net Sales of $64 . 3 M illion , Above Preliminary Range

MiMedx Announces Third Quarter 2020 Financial Results

MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today confirmed that the Company's common stock will commence trading on The Nasdaq Stock Market at the opening of trading on Wednesday, November 4, 2020, under the ticker symbol “MDXG”.

MiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020

Only Amniotic Product Covered Under Updated Commercial Policy

MiMedx Announces Largest U.S. Commercial Payor Will Provide Coverage for EpiFix in the Treatment of Diabetic Foot Ulcers

MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that The Nasdaq Stock Market LLC has approved MiMedx's application for the relisting of the Company's common stock on The Nasdaq Stock Market. The Company's common stock is expected to commence trading on The Nasdaq Stock Market at the opening of trading on or before Thursday, November 5, 2020, under the ticker symbol “MDXG”. MiMedx's common stock will continue to trade on the OTC Pink Sheets until market close on the date before listing on the Nasdaq Stock Market under the ticker symbol "MDXG".

MiMedx Announces Relisting on Nasdaq

MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the third quarter ended September 30, 2020 after the market close on Wednesday, November 4, 2020. MiMedx management will host a webcast and conference call to review its third quarter 2020 results on Thursday, November 5, 2020, beginning at 8:30 am, Eastern Time. Participating on the call will be Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer.

MiMedx to Host Third Quarter 2020 Financial Results Call on November 5

MARIETTA, Ga., Oct. 15, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“ SEC ”) in connection with its upcoming 2020 Annual Meeting of Shareholders (“ Annual Meeting ”). The meeting is scheduled to be held on Friday, November 20, 2020 at 10:00 a.m. Eastern Time at www.virtua lshareholdermeeting.com/MDXG2020. Shareholders as of the record date, 5:00 p.m. Eastern Time on Wednesday, October 7, 2020, are entitled to notice of, and to vote at, the Annual Meeting.

MiMedx Files Definitive Proxy Materials

Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally

MiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee

Third Quarter 2020 Net Sales Expected to be  Between  $61 Million - $64 Million

MiMedx Announces Preliminary Third Quarter 2020 Net Sales

Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders

MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial

New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade

MiMedx Launches EpiCord Expandable Placental Allograft as Addition to Market Leading Portfolio

MARIETTA, Ga., Aug.  24, 2020  (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today provided additional information about its upcoming virtual 2019 Annual Meeting of Shareholders (“ Annual Meeting ”). Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, are scheduled to present an overview of the Company, its strategic priorities and key areas of focus for future growth. Additional members of senior management also plan to be available for a question and answer session open only to shareholders as of the record date of 5:00 p.m. Eastern Time on July 14, 2020. Guests may join the virtual 2019 Annual Meeting in a listen-only mode without a control number.

MiMedx to Discuss Strategic Priorities at Upcoming Virtual 2019 Annual Meeting of Shareholders

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q2 2020 Results - Earnings Call Transcript

Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities

MiMedx Welcomes Robert B. Stein, M.D.

Second Quarter Net Sales of $53.6 million

MiMedx Files Second Quarter 2020 Form 10-Q

Strategic Leader with Proven Record of Delivering Growth and Business Transformation Strategic Leader with Proven Record of Delivering Growth and Business Transformation

MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer

MiMedx Fixes Cash Concerns With Relisting Right Around The Corner

Company Now Caught Up in Financial Reporting

MiMedx Announces Filing of 2020 First Quarter Form 10-Q

Annual Report on Form 10-K includes Audited Financial Results for 2019

MiMedx Announces Filing of 2019 Annual Report

Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management

MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

March Flowers Could Bring MiMedx Showers Of Shareholder Returns

MiMedx Group Inc. MDXG, +0.08% said Tuesday it has reached a settlement with the Securities and Exchange Commission to resolve a probe of its accounting practices.

MiMedx to pay $1.5 million to settle SEC probe of accounting practices

10 Reasons To Buy MiMedx Stock Today

A timetable of upcoming catalysts points to impressive upside potential by the end of 2019 and the beginning of 2020.

MiMedx - All In On This Home Run Stock

August starts the watch for restatements of MiMedx's financials possibly right before the company's yet to be scheduled 2019 Annual Meeting.

MiMedx: Could Finish 2018 With A Bang While 2020 Could Be Even Better

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

News for MiMedx Group Stock (MDXG)